Trial reportChinese journal of integrative medicine2026
Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial.
Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy and safety of Xueshuantong Injection (Lyophilized) (XST) in reducing residual inflammatory risk (RIR) in patients with unstable angina (UA).
methodsThis was a randomized, double-blind, parallel-controlled multicenter trial. Patients with UA were recruited from Xiyuan Hospital and Guang'anmen Hospital of the China Academy of Chinese Medical Sciences between January 2024 and March 2025. Eligible participants were randomly assigned to the treatment group (XST 500 mg, 30 cases) or the control group (XST 25 mg, 30 cases) in a 1:1 ratio. Both groups received intravenous XST for 10 consecutive days along with standard medical therapy. The primary outcome was change in C-reactive protein (CRP) level from baseline to post-treatment. Secondary outcomes included changes in interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), high-mobility group box 1 (HMGB1), vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF), as well as the Canadian Cardiovascular Society (CCS) classification, and Chinese Medicine (CM) syndrome scores. Safety was evaluated by monitoring adverse event (AE) and performing laboratory tests of liver and kidney function before and after treatment.
resultsA total of 59 patients completed the trial (30 in the treatment group and 29 in the control group). After treatment, the treatment group showed significantly greater reductions in CRP levels compared to the control group (P<0.01). In addition, the treatment group exhibited significantly improved IL-6, MMP-9, and HMGB1 levels, as well as CM symptom scores and CCS classification compared to the control group (all P<0.05). No serious adverse events were reported. Compared with the control group, the treatment group receiving XST showed greater improvements in RIR and clinical symptoms in UA patients with good safety and tolerability.
conclusionXST shows potential to reduce RIR in patients with UA and may inform anti-inflammatory management. (Registration No. ITMCTR2025000552).
Indexed as
Identifiers
41111082What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.